Feb 10, 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Dec 13, 2019
ITF Pharma Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIGLUTIK® (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) with a Percutaneous Endoscopic Gastronomy (PEG) Feeding Tube
Jul 19, 2019
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
Apr 16, 2019
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
Mar 14, 2019
Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
Feb 28, 2019
ITF Pharma Receives Patient Impact Award for First and Only Easy-To-Swallow Thickened Liquid Treatment for Amyotrophic Lateral Sclerosis (ALS)
Feb 20, 2019
Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
Nov 26, 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Oct 15, 2018
ITF Pharma Announces Availability Of TIGLUTIK(TM) (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) In The United States
Sep 06, 2018
ITF Pharma Announces FDA Approval Of TIGLUTIK(TM) (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Aug 16, 2018
Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
May 15, 2018
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
May 09, 2018
Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)
Mar 06, 2018
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results
Jan 31, 2018
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS
Jan 09, 2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
Nov 06, 2017
Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223
Nov 01, 2017
Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS)